Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,726.01
(
0.40%
)
US TECH 100
24,177.20
(
0.67%
)
Dow Jones
47,073.53
(
0.27%
)
Brent Oil
100.73
(
2.47%
)
Bitcoin
74,606.85
(
-0.32%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 76008

Tuesday, 04/21/2009 1:05:03 AM

Tuesday, April 21, 2009 1:05:03 AM

Post# of 257251
BSX’s 1Q09 market share in drug-eluting stents:

US
Taxus 27%
Promus* 23%
===
50%

Ex-Us
44%

http://finance.yahoo.com/news/Boston-Scientific-Announces-prnews-14977987.html

*Promus is ABT’s Xience stent combined with BSX’s delivery system; BSX sells Promus pursuant to its divestiture of Guidant’s vascular business to ABT in order to satisfy anti-trust considerations.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now